Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1349 | Eicosapentaenoic acid gastro-resistant capsules Wiki | 0.45 |
| drug1934 | Informational videos and social media campaigns encouraging cancer screening. Wiki | 0.45 |
| drug1354 | Electric pad for human external pain therapy Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug982 | Colorectal resections Wiki | 0.45 |
| drug4279 | Wait list time Wiki | 0.45 |
| drug4448 | ctDNA blood sampling Wiki | 0.45 |
| drug1361 | Electronic Survey questionnaire Wiki | 0.45 |
| drug3657 | Social comparison Intervention Wiki | 0.45 |
| drug3735 | Standard of Care Treatment Wiki | 0.45 |
| drug1106 | Crisis management coaching Wiki | 0.45 |
| drug2112 | Leadership Training Wiki | 0.45 |
| drug3723 | Standard communication email Wiki | 0.45 |
| drug832 | Camostat Mesilate Wiki | 0.16 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D015179 | Colorectal Neoplasms NIH | 1.00 |
| D046152 | Gastrointestinal Stromal Tumors NIH | 0.45 |
| D002690 | Chlamydia Infections NIH | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100574 | Biliary tract neoplasm HPO | 0.45 |
| HP:0009725 | Bladder neoplasm HPO | 0.45 |
| HP:0100723 | Gastrointestinal stroma tumor HPO | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030079 | Cervix cancer HPO | 0.32 |
| HP:0100526 | Neoplasm of the lung HPO | 0.13 |
| HP:0002664 | Neoplasm HPO | 0.07 |
Navigate: Correlations HPO
There are 5 clinical trials
As part of UCLA Health's commitment to developing a premier integrated health system built on a foundation of physician-led, team-based primary care, the Department of Medicine (DOM) recently implemented a new performance based incentive plan called the Primary Care Clinical Excellence (PCCE) Incentive Plan. This incentive plan was developed to motivate providers to improve health maintenance screening rates. The UCLA Health DOM Quality team is leading the implementation and evaluation of this new incentive plan across our primary care network. In addition, the DOM Quality team has partnered with the UCLA Anderson School of Management to study the most efficacious ways to frame and communicate performance based incentives. Understanding the factors that motivate physicians to deliver the highest quality primary care will provide pivotal insights into the successful implementation of performance based programs nationwide. The investigators believe that physicians who receive communication built on behavioral principles will demonstrate more motivation towards and success at meeting national primary care screening guidelines.
Description: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, we will consider all Focus Quality Measures open at his/her first visit to the PCP, and calculate the percent of these measures ordered within 7 days following his/her first visit. Focus Quality Measures include: Diabetes HGB A1C, Diabetes Eye Exam, Diabetes Foot Exam, Diabetes Nephropathy Monitoring, Colon Cancer Screening, Breast Cancer screening, Cervical Cancer Screening, chlamydia screening, and HPV depending on primary care specialty. These Focus Measures are based on the USPSTF primary care recommendations. [Note: The original intent was to run the study over an eight month period - from November 1, 2019 through June 30, 2020 - but was cut short due to the COVID-19 pandemic. Our revised time frame includes (1) four full cycles (months) of the intervention (11/05/2019-03/03/2020) and four months prior to the experiment as a baseline period]
Measure: Aggregate Focus Quality Measure order rates at the first visit Time: 9 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, we will consider all Focus Quality Measures that are open between November 5, 2019 and March 3, 2020. We will calculate the percentage of these measures completed between November 5, 2019 and March 10, 2020 as well as the percentage completed between November 5, 2019 and July 3, 2020.
Measure: Aggregate Focus Quality Measure completion rates measured at the patient level Time: 13 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, for each Focus Quality Measure open at his/her first visit to the PCP, we will assess whether the open measure is ordered within 7 days following his/her first visit.
Measure: Individual Focus Quality Measure order status at the first visit Time: 9 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, for each Focus Quality Measure open between November 5, 2019 to March 3, 2020, we will assess whether the measure is completed (1) between November 5, 2019 and March 10, 2020 as well as (2) between November 5, 2019 and July 3, 2020.
Measure: Individual Focus Quality Measure completion status at the patient level Time: 13 monthsDescription: As measured by aggregate order rates for Complementary Health Maintenance Measures within seven days after each patient's first visit. Complementary Measures (Abdominal Aortic Aneurysm Screening, Osteoporosis Screening, Hepatitis C Screening, HIV Screening, Pneumococcal Vaccination, Tetanus Vaccination, Tdap Vaccination During Pregnancy, Shingles Vaccination, Meningitis Vaccination, Measles Mumps Rubella Vaccination, Polio Vaccination, Hepatitis A Vaccination, Hepatitis B vaccination, Pneumococcal Vaccination for Patients with Diabetes, Statin for Primary ASCVD Prevention, Aspirin for Secondary ASCVD Prevention, and Annual Wellness Visit) are based on USPSTF primary care recommendations regarding disease management, infectious disease screening, and standard vaccinations.
Measure: Complementary Health Maintenance order rate at the first visit Time: 9 monthsDescription: As measured by patient level aggregate performance Complementary Health Maintenance Measures (1) between November 5, 2019 and March 10, 2020 as well as (2) between November 5, 2019 and July 3, 2020.
Measure: Complementary Health Maintenance completion rate at the patient level Time: 13 monthsDescription: Physicians will be surveyed to evaluate their level of burnout throughout the study period.
Measure: Physician Burnout Time: 9 monthsDescription: Physicians will be surveyed for their satisfaction throughout the study period.
Measure: Physician Satisfaction Time: 9 monthsDescription: Physicians will be surveyed regarding their provider experience throughout the study period.
Measure: Physician Experience Time: 1 yearDescription: Payment of performance based financial incentive to physicians throughout the study period.
Measure: Physician Incentive Payouts Time: 1 yearDescription: Physician performance in patient satisfaction surveys throughout the study period.
Measure: Patient Satisfaction Time: 1 yearDescription: Physician performance in professional participation will be based on provider/physician surveys throughout the study period.
Measure: Profesional Participation Time: 1 yearDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, we will consider all Focus Quality Measures that are open between November 5, 2019 and March 3, 2020, and calculate the percentage of these measures ordered between November 5, 2019 and March 10, 2020.
Measure: Aggregate Focus Quality Measure order rates measured at the patient level Time: 9 monthsDescription: HM order rate is determined by the aggregate order rate of measures within the primary care Health Maintenance module of EPIC EHR ("Focus Quality Measures") and other Quality Measures that are not in the Health Maintenance module ("Complementary Measures"). Both the Focus Quality Measures and Complementary Measures are based on USPSTF primary care recommendations regarding disease management, infectious disease screening, cancer screening, and standard vaccinations.
Measure: Aggregate Health Maintenance (HM) order rates measured at the patient level Time: 9 monthsDescription: HM completion rate is determined by the aggregate completion rate of variables within the primary care Health Maintenance module of EPIC EHR ("Focus Quality Measures") and other Quality Measures that are not in the Health Maintenance module ("Complementary Measures").
Measure: Aggregate Health Maintenance (HM) completion rates measured at the patient level Time: 13 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, for each Focus Quality Measure open between November 5, 2019 to March 3, 2020, we will assess whether the measure is ordered between November 5, 2019 and March 10, 2020.
Measure: Individual Focus Quality Measure order status at the patient level Time: 9 monthsDescription: For each primary care physician, we assign patients to their panel using an attribution model. This model assigns patients to a physician if they have been seen by that physician within the last 3 years. Additional patient attribution logic includes: 1) the physician with a preventive/wellness visit in the prior 1 year is attributed first, 2) if there is no preventive/wellness visit in the prior 1 year, the physician with the largest number of visits is attributed, and 3) if there is a tie in either the preventive/wellness visit or number of visit scenario, the physician with the most recent visit is attributed. Once patients are assigned using the above attribution model, patients who have at least one visit with their attributed physician from November 5, 2019 to March 3, 2020 will be included in our evaluation.
Measure: The proportion of patients in the panel who visited a given physician Time: 6 monthsDescription: For each physician, we will identify the number of new patients they have from November 5, 2019 to March 3, 2020.
Measure: New Patients Time: 6 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, we will measure the total number of times he/she visits the PCP from November 5, 2019 to March 3, 2020.
Measure: Number of Visits Time: 6 monthsDescription: For each patient who visits a given PCP in our sample from November 5, 2019 to March 3, 2020, we will measure the number of open measures he/she has at the first visit as well as the total number of open measures he/she has from November 5, 2019 to March 3, 2020.
Measure: Number of Open Tests Time: 6 monthsThis work is an original clinical research article describing the relationship between wait list tome for colorectal cancer patients and long-term survival. These findings are particularly relevant for management of surgical wait lists during crisis such as the Covid-19 pandemic. The lack of a relationship between wait list time and disease free survival and tendency for improved survival in the 4-6 week imply some colorectal cancer operations can be safely delayed during times of limited resources.
The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.
Description: The primary endpoint, ctDNA detection rate, overall and within different cancer types will be presented as a proportion of patients with a positive ctDNA test out of those tested, with 90% confidence intervals
Measure: ctDNA detection rate within different cancer types (and overall) Time: Throughout study completion, up to one yearDescription: All secondary endpoints will be analysed in the patients diagnosed with suspected cancer, i.e. positive ctDNA result, unless stated. They will also be presented overall and by cancer type. The proportion of patients with positive ctDNA result which identified a diagnosis and/or commenced treatment will be presented as a proportion with 90% confidence intervals
Measure: Proportion of patients with a positive ctDNA result which identified a diagnosis and/or commenced treatment Time: Throughout study completion, up to one yearDescription: Proportion of patients with positive ctDNA result which assisted in prioritising invasive diagnostic tests will be presented as a proportion with 90% confidence intervals
Measure: Proportion of patients with a positive ctDNA result which assisted in prioritising invasive diagnostic tests Time: Throughout study completion, up to one yearDescription: The association between ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result will be assessed descriptively by presenting cross-tabulations and relevant proportions
Measure: The association of ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result Time: Throughout study completion, up to one yearDescription: Simple estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation will be performed
Measure: Estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation Time: Throughout study completion, up to one yearLifespan Cancer Institute serves over 50% of cancer patients in the state. Rhode Island is known for strong medical care and high rates of cancer screening with mammography and colonoscopy. However, cancer screening has plummeted during the COVID-19 pandemic, in part to closing physician offices and stopping non-urgent medical procedures. In addition, anecdotal reports suggest the public remains concerned about returning to physician's offices and risking possible exposure to COVID-19. As in the United States as a whole, COVID-19 has disproportionately impacted ethnic and minority individuals within underserved communities; and in Rhode Island, African Americans, Hispanics and undocumented individuals living in communities such as Central Falls, Pawtucket, Providence, East Providence and North Providence have had the highest rate of COVID-19. These communities are also impacted by healthcare disparities to access and affordability of healthcare, and as such, may be among the least likely to resume cancer screening. The Lifespan Cancer Institute will institute a project to address health disparities in cancer screening during the pandemic through the use of a targeted campaign involving social media. The goals will be to re-establish screening in the era of COVID-19 and ensure timeliness of care for those found to be at risk, or are positive for, cancer.
Description: Increase screening rates for breast and colorectal cancer among underserved populations by 25% using March 9 through May 31 as a benchmark, coinciding the Executive Orders for COVID19 announced by Governor Raimondo.
Measure: Increase screening rates for breast and colorectal cancer Time: 2 yearsDescription: Evaluate the impact of screening on timeliness of cancer care among these populations by comparing to the American Society of Clinical Oncology's Quality Oncology Performance Initiative (QOPI) guidelines in breast and colorectal cancer.
Measure: Impact of screening on cancer care Time: 2 yearsDescription: Evaluate strategies of engagement in these communities as it relates to: -Social media platform (Twitter, Facebook, Instagram, TikTok) These metrics will be determined by social media statistics for engagement and the number of calls/queries to the designated information lines.
Measure: Community Engagement Time: 2 YearsDescription: Evaluate barriers to cancer screening in these populations as it particularly relates to COVID19.
Measure: Barriers to cancer screening during COVID19. Time: 2 YearsDescription: We will educate staff, community physicians and Rhode Island residents on the importance of cancer screening. We will use community-based partnerships to overcome distrust of institutions and develop an engaged community network. Long term academic goals include publication of data and successfully receiving local and federal funding for continued research.
Measure: Educate the community on the importance of cancer screening Time: 5-10 yearsDue to COVID 19 (Corona virus disease)pandemic, majority of surgeries, including surgery for cancer patients got delayed across the globe. Surgeries were limited to emergency set up only. At our institute we tried to perform colorectal cancer surgeries through out the pandemic, albeit in less numbers, as we thought cancer in itself is an emergency setting. we are planning to analyse the prospectively managed database of this particular group of patients over a period of last six 6 months and look out at 30 day post operative morbidity and mortality. Besides we will try to analyse the implications of our decision to carry on with cancer surgeries in terms of number of health care workers who got infected while being involved in primary care of these patients.
Description: patients who died within 30 days following their surgery
Measure: Early post operative mortality Time: 30 daysDescription: post operative complications will be graded as per clavien dindo grading system
Measure: Early Post operative complications Time: 30 daysDescription: determine whether any health care worker involved with the care of this cohort of patients got infected with SARS CoV 2.
Measure: Incidence of SARS CoV2 infectivity among health care providers providing direct care to involved patients Time: 30 daysDescription: Determine whether any patient from the cohort got infected with SARS CoV 2 during their hospital stay or immediately after discharge
Measure: Rate of hospital acquired SARS CoV 2 infection among operated patients. Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports